Metabolic syndrome common in young women with lupus
Luciana F. Muniz, M.D., from Faculdade de Medicina da Universidade de Sao Paulo in Brazil, and colleagues evaluated the frequency of metabolic syndrome and disease- or therapy-related factors in 103 premenopausal SLE patients (<40 years) and 35 healthy, premenopausal, age-matched women.
The researchers found a higher frequency of metabolic syndrome in the SLE group (22.3 percent versus 5.7 percent; P=0.03). Compared with those without metabolic syndrome, SLE patients with metabolic syndrome had higher SLE Disease Activity Index scores (P=0.006), more frequently had previous renal disease (73.9 percent versus 51.2 percent; P=0.05) and current renal disease (34.8 percent versus 10 percent; P=0.008), and had higher current prednisone dose (P=0.018) and cumulative prednisone dose (P=0.023). Chloroquine was less frequently used in metabolic syndrome-SLE patients (65.2 percent versus 90 percent; P=0.008). In multivariate analysis, only current chloroquine use (prevalence ratio [PR], 0.29) and cumulative prednisone were associated with metabolic syndrome (PR, 1.02).
"Chloroquine has a protective effect on the prevalence of metabolic syndrome in these patients, and this benefit counteracts the deleterious effect of glucocorticoids in a dose-dependent manner," the authors conclude.
Full Text (subscription or payment may be required)
Copyright © 2015 HealthDay. All rights reserved.